DelveInsight

更年期における血管運動性症状:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Vasomotor Symptoms of Menopause – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vasomotor Symptoms of Menopause development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Vasomotor Symptoms of Menopause
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Vasomotor Symptoms of Menopause
The report assesses the active Vasomotor Symptoms of Menopause pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Vasomotor Symptoms of Menopause
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Vasomotor Symptoms of Menopause
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Vasomotor Symptoms of Menopause
• The report also covers the dormant and discontinued pipeline projects related to the Vasomotor Symptoms of Menopause

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Vasomotor Symptoms of Menopause to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Vasomotor Symptoms of Menopause therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

血管炎:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Vasculitis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vasculitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Vasculitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Vasculitis
The report assesses the active Vasculitis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Vasculitis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Vasculitis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Vasculitis
• The report also covers the dormant and discontinued pipeline projects related to the Vasculitis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Vasculitis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Vasculitis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

血管性認知症:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Vascular Dementia – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vascular Dementia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Vascular Dementia
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Vascular Dementia
The report assesses the active Vascular Dementia pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Vascular Dementia
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Vascular Dementia
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Vascular Dementia
• The report also covers the dormant and discontinued pipeline projects related to the Vascular Dementia

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Vascular Dementia to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Vascular Dementia therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

水痘帯状疱疹(HHV-3)感染症:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Varicella Zoster (HHV-3) Infections – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Varicella Zoster (HHV-3) Infections development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Varicella Zoster (HHV-3) Infections
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Varicella Zoster (HHV-3) Infections
The report assesses the active Varicella Zoster (HHV-3) Infections pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Varicella Zoster (HHV-3) Infections
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Varicella Zoster (HHV-3) Infections
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Varicella Zoster (HHV-3) Infections
• The report also covers the dormant and discontinued pipeline projects related to the Varicella Zoster (HHV-3) Infections

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Varicella Zoster (HHV-3) Infections to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Varicella Zoster (HHV-3) Infections therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

帯状疱疹(HHV-3)感染症:パイプラインインサイト2018

2018年2月9日 // 0 Comments

” Varicella Zoster (HHV-3) Infections – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across  Varicella Zoster (HHV-3) Infections development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for  Varicella Zoster (HHV-3) Infections
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for  Varicella Zoster (HHV-3) Infections
The report assesses the active  Varicella Zoster (HHV-3) Infections pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the  Varicella Zoster (HHV-3) Infections
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the  Varicella Zoster (HHV-3) Infections
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for  Varicella Zoster (HHV-3) Infections
• The report also covers the dormant and discontinued pipeline projects related to the  Varicella Zoster (HHV-3) Infections

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this  Varicella Zoster (HHV-3) Infections to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of  Varicella Zoster (HHV-3) Infections therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

バンコマイシン耐性エンテロコッカス・フェシウム感染症:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Vancomycin-Resistant Enterococcus Faecium Infections – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vancomycin-Resistant Enterococcus Faecium Infections development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Vancomycin-Resistant Enterococcus Faecium Infections
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Vancomycin-Resistant Enterococcus Faecium Infections
The report assesses the active Vancomycin-Resistant Enterococcus Faecium Infections pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Vancomycin-Resistant Enterococcus Faecium Infections
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Vancomycin-Resistant Enterococcus Faecium Infections
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Vancomycin-Resistant Enterococcus Faecium Infections
• The report also covers the dormant and discontinued pipeline projects related to the Vancomycin-Resistant Enterococcus Faecium Infections

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Vancomycin-Resistant Enterococcus Faecium Infections to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Vancomycin-Resistant Enterococcus Faecium Infections therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

膣炎:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Vaginitis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Vaginitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Vaginitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Vaginitis
The report assesses the active Vaginitis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Vaginitis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Vaginitis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Vaginitis
• The report also covers the dormant and discontinued pipeline projects related to the Vaginitis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Vaginitis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Vaginitis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

ぶどう膜炎:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Uveitis – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Uveitis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Uveitis
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Uveitis
The report assesses the active Uveitis pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Uveitis
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Uveitis
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Uveitis
• The report also covers the dormant and discontinued pipeline projects related to the Uveitis

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Uveitis to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Uveitis therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

ぶどう膜黒色腫:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Uveal Melanoma – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Uveal Melanoma development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Uveal Melanoma
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Uveal Melanoma
The report assesses the active Uveal Melanoma pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Uveal Melanoma
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Uveal Melanoma
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Uveal Melanoma
• The report also covers the dormant and discontinued pipeline projects related to the Uveal Melanoma

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Uveal Melanoma to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Uveal Melanoma therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

子宮平滑筋腫(子宮筋腫):パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Uterine Leiomyoma (Uterine Fibroids) – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Uterine Leiomyoma (Uterine Fibroids) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Uterine Leiomyoma (Uterine Fibroids)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Uterine Leiomyoma (Uterine Fibroids)
The report assesses the active Uterine Leiomyoma (Uterine Fibroids) pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Uterine Leiomyoma (Uterine Fibroids)
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Uterine Leiomyoma (Uterine Fibroids)
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Uterine Leiomyoma (Uterine Fibroids)
• The report also covers the dormant and discontinued pipeline projects related to the Uterine Leiomyoma (Uterine Fibroids)

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Uterine Leiomyoma (Uterine Fibroids) to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Uterine Leiomyoma (Uterine Fibroids) therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

尿路感染症:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Urinary Tract Infections – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Urinary Tract Infections development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Urinary Tract Infections
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Urinary Tract Infections
The report assesses the active Urinary Tract Infections pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Urinary Tract Infections
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Urinary Tract Infections
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Urinary Tract Infections
• The report also covers the dormant and discontinued pipeline projects related to the Urinary Tract Infections

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Urinary Tract Infections to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Urinary Tract Infections therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

尿失禁:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Urinary Incontinence – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Urinary Incontinence development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Urinary Incontinence
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Urinary Incontinence
The report assesses the active Urinary Incontinence pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Urinary Incontinence
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Urinary Incontinence
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Urinary Incontinence
• The report also covers the dormant and discontinued pipeline projects related to the Urinary Incontinence

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Urinary Incontinence to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Urinary Incontinence therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

尿素サイクル異常症:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Urea Cycle Disorders – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Urea Cycle Disorders development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Urea Cycle Disorders
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Urea Cycle Disorders
The report assesses the active Urea Cycle Disorders pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Urea Cycle Disorders
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Urea Cycle Disorders
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Urea Cycle Disorders
• The report also covers the dormant and discontinued pipeline projects related to the Urea Cycle Disorders

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Urea Cycle Disorders to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Urea Cycle Disorders therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

チフス熱:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Typhoid Fever – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Typhoid Fever development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Typhoid Fever
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Typhoid Fever
The report assesses the active Typhoid Fever pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Typhoid Fever
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Typhoid Fever
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Typhoid Fever
• The report also covers the dormant and discontinued pipeline projects related to the Typhoid Fever

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Typhoid Fever to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Typhoid Fever therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

野兎病:パイプラインインサイト2018

2018年2月9日 // 0 Comments

“Tularaemia – Pipeline Insight, 2018” report by DelveInsight offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Tularaemia development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:
• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Tularaemia
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Tularaemia
The report assesses the active Tularaemia pipeline products by developmental stage, product type, molecule type, and administration route.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
• The report provides a snapshot of the pipeline development for the Tularaemia
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Tularaemia
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Tularaemia
• The report also covers the dormant and discontinued pipeline projects related to the Tularaemia

Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Tularaemia to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Tularaemia therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

1 2 3 4 24